Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep;171 Suppl 1(Suppl 1):6-35.
doi: 10.1002/ijgo.70282.

Cancer of the ovary, fallopian tube, and peritoneum: 2025 update

Malte Renz  1 , Michael Friedlander  2   3 , Jonathan S Berek  4
Affiliations
Review

Cancer of the ovary, fallopian tube, and peritoneum: 2025 update

Malte Renz et al. Int J Gynaecol Obstet. 2025 Sep.

Abstract

In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSCs). Stage IC is now divided into three categories: IC1 (surgical spill), IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface), and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension) and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now "microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node" metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, including the treatment of ovarian germ cell and stromal malignancies.

Keywords: FIGO cancer report; cancer staging; chemotherapy; fallopian tube; ovary; peritoneum.

PubMed Disclaimer

Conflict of interest statement

MR has nothing to disclose. MF receives honoraria for advisory boards from Astra Zeneca, GSK, MSD, Lilly, Novartis, and Takeda; speakers fees from Astra Zeneca; and institutional research funding from Astra Zeneca, Novartis, and Beigene. JB receives institutional research funding from Eisai, Immunogen, Tesaro; honoraria for DSMB from Merck.

References

    1. Berek JS, Friedlander M, Hacker NF. Epithelial ovarian, fallopian tube, and peritoneal cancer. In: Berek JS, Hacker NF, eds. Berek and Hacker's Gynecologic Oncology. Wolters Kluwer; 2021.
    1. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology. Armed Forces Institute of Pathology; 1998:1‐168.
    1. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161‐169. - PubMed
    1. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA‐positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25(25):3985‐3990. - PubMed
    1. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27(2):151‐160. - PMC - PubMed

LinkOut - more resources